Pall Corporation to Acquire ATMI's LifeSciences Business for $185 million - - BioPharm International

ADVERTISEMENT

Pall Corporation to Acquire ATMI's LifeSciences Business for $185 million


Pall Corporation, a solutions provider in filtration, separation and purification, has signed a definitive agreement with ATMI to acquire ATMI’s LifeSciences business unit for $185 million. ATMI LifeSciences specializes in single-use bioprocess systems and consumables for the bio/pharmaceutical industry. According to the press release, the transaction is expected to close in Pall’s fiscal third quarter and will be subject to closing conditions, regulatory approvals and labor-related notifications.

Pall announced that for the balance of fiscal 2014, the company expects the acquisition to add $20 $30 million in revenue, be $0.05–$0.08 dilutive to EPS on a GAAP basis and almost breakeven on a cash EPS basis. Pall reaffirms its total overall fiscal 2014 guidance for pro forma EPS to be $3.30–$3.50.

Source: Pall Corporation

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

J&J Speeds Ebola Vaccine Development and Expands Production
October 24, 2014
Despite AbbVie Snub, Shire Says it Will Double Sales by 2020
October 24, 2014
Manufacturing Challenges of mAb Production: CHO or Plant Cells?
October 24, 2014
Celgene and Sutro Partner on ADC Development
October 24, 2014
GSK Accelerates Ebola Vaccine Development
October 24, 2014
Author Guidelines

Click here